key: cord-0848286-deg4d8co
authors: Ebrahimi, Mahmoud; Farhadian, Nafiseh; Amiri, Ali Reza; Hataminia, Fatemeh; Soflaei, Sara Saffar; Karimi, Mohammad
title: Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID‐19: A clinical study
date: 2021-08-26
journal: J Med Virol
DOI: 10.1002/jmv.27273
sha: 9e03e24b1ec2a299ae39e189b0f230e7dead8707
doc_id: 848286
cord_uid: deg4d8co

This study investigates the effect of the nanostructure of squalene in the form of microemulsion on COVID‐19 patients. In this blinded clinical trial, a comparison was made between the efficacy of squalene treatment and controls. A total of 30 COVID‐19 patients admitted to the emergency department, and the infection ward was equally allocated to case (n = 15) and control (n = 15) groups according to their age and underlying diseases. The baseline characteristics of subjects, including age, gender, time of treatment onset, underlying condition, white blood cells count, and lymphocyte count were similar (p < 0.05). Baseline laboratory tests and computed tomography (CT) scans were performed for the study groups. The treatment group received 5 mg of intravenous squalene twice a day and standard treatment for 6 days, while controls received only standard treatment. After 6 days of treatment, clinical and CT scan changes were evaluated and compared in intervention and control groups. The need for oxygen therapy (p = 0.020), 2 days of no fever (p = 0.025), cough alleviation (p = 0.010), and lung high‐resolution computed tomography improvement (p = 0.033) were significantly different between cases and controls within 7 days of admission. No adverse effects were observed in the treatment group. Our data suggest that squalene could be considered as a potential treatment for COVID‐19, and further studies are required to confirm the results.

high in critically ill patients, which results in cytokine storm syndrome and hyper-inflammation of the pathogenesis of COVID-19. 6, 7 In contrast, oxidative stress is also hypothesized to account for SARS-CoV-2 infection pathogenesis, which involves in a cytokine storm, coagulopathy, and cell hypoxia. 8 The urgent need for an efficacious treatment has initiated a global race to find a novel or repurposed antiviral medicine. For this purpose, several therapeutic agents have been evaluated; nonetheless, many clinical trials are still running, and so far, only Remdesivir has been approved by FDA for COVID-19 treatment, and the need for therapeutic development persists. 9, 10 Recently, there has been a rising demand for herbal and organic substances for treating and preventing medical conditions, and they have provided a valuable source of medical discoveries. Terpenoids, also known as Isoprenoids, are a broad group of natural products in many plants and demonstrate a wide range of biological activities. 11 They are classified into several subclasses based on their isoprene subunit number including hemiterpenes, sesquiterpenes, triterpenes, tetraterpenes, and polyterpenes. 12 Terpenoids are effective against cancer, inflammation, malaria, and various infectious diseases with multiple medical and therapeutic applications (e.g., Paclitaxel is an anticancer, and Artemisinin is an antimalaria drug). 11 Squalene (SQ) is a natural lipophilic biomolecule that belongs to the chemical class of triterpenes. With a formula of C30H50, it acts as a precursor of sterols and other bioactive terpenoids. 13 There is a small amount of this antioxidant component in the human body (skin, liver, and intestine). It can be extracted from shark liver oil or some plant oils. 14 Various studies exhibited certain bioactivities of this molecule, including antioxidant, antineoplastic, 15, 16 and antiatherosclerotic properties, 17, 18 and a chemopreventive effect. 19 SQ, as an effective ingredient in MF59, is a safe and potent influenza vaccine adjuvant. It can improve the immunogenicity of vaccines even in immunocompromised patients [20] [21] [22] without stimulating antibody response. 23 It is believed that SQ possesses anti-inflammatory effects. 17, 24 This natural substance prevents the over-activation of neutrophils and monocytes and increases anti-inflammatory enzymes. 24 In addition, the antioxidant feature of SQ highlighted in several studies could be linked to SQ molecular features, which makes it an efficient quencher of singlet oxygen and free radicals. [25] [26] [27] The antiviral, antifungal, and antimicrobial effects of terpenoids have been evaluated recently, and they are presumed to provide a promising novel antiviral medicine. 28, 29 Terpenoids appear to act as an antiviral agent by activating membrane-mediated mechanisms and inhibiting viral DNA synthesis. 30 In contrast, several studies have revealed the antiviral effect of some natural herbs against SARS-CoV. [31] [32] [33] Glycyrrhizin, a triterpenoid compound, exhibits anti-SARS-CoV activity, which can completely block virus replication in high concentrations. 31, 34 The antiviral effect of SQ in treating the hepatitis C virus has been shown in a patent. 35 Due to the lipophilic structure of SQ, oil-in-water microemulsions can offer a suitable form for SQ intravenous injection. The safety and biocompatibility of SQ microemulsions have been shown in various studies. [36] [37] [38] [39] Developing novel therapeutics is crucial, but formulating new drugs and evaluating their safety and efficacy in a short time seems impractical due to the time-consuming nature of this process. Therefore, it is reasonable to examine substances with confirmed antiviral potentials that are safe and well-tolerated. Given that SQ possesses anti-inflammatory, immunomodulatory, and antioxidant features with minimum side effects, it might affect SARS-CoV-2 infection as well. Accordingly, this clinical trial aims to obtain an effective SQ-based formulation to examine the therapeutic effect of SQ among COVID-19 patients. SQ was extracted from natural oil of high purity. To the best of our knowledge, this is the first study that investigates the SQ effect on SARS-CoV-2 infection. 

FeCl 3 • 6H 2 O (97%), FeCl 2 • 4H 2 O (99%),

The microemulsion containing SQ with a concentration of 10 mg/ml was prepared using the titration method. 42 These mass ratios were selected based on the SQ ternary phase diagram. 44 At last, 10 mg SQ, 45 mg Tween 80, 5 mg Span 80, and 1 ml water was applied for microemulsion preparation. By using these contents, it is expected to prepare a microemulsion with appropriate particle size for IV usage.

GC-FID analysis specification (6890 Series GC system) was applied to measure the purity of extracted squalene. 41 Microemulsion samples were centrifuged (Sigma3-30k) at 10,000 rpm for 15 min at 25°C for the physical stability study. They were assumed as physically stable provided that no sign of drug precipitation, droplet conjugation, creaming, and phase separation was observed. The stability of samples over time was examined 3 and 6 months after preparation using droplet size determination. A significant increase in the average droplet size, polydispersity index, and unfavorable particle size distribution over time were considered as signs of instability over time. In addition, thermal stability studies of microemulsion at 4°C, 25°C, and 40°C were evaluated via clarity and phase separation observation.

The microemulsion sample was centrifuged at 10,000 rpm for 15 min.

A volume of 1 ml of the sedimented microemulsion sample was dissolved in 10 ml of hexane, which can dissolve SQ completely. The solution was analyzed by GC. The content of SQ in the microemulsion was determined based on the GC diagram and SQ calibration curve. By dividing the computed value by the initial SQ amount, the percentage of drug content was determined.

The sample was selected from adults admitted to the emergency department and infectious ward of Shohada hospital. The patients with diagnostic signs and symptoms of COVID-19 including acute loss of sense and smell, fever, dry cough, fatigue, lymphocytopenia, elevated c-reactive protein (CRP), with/without contact with confirmed cases of COVID-19, patients with diagnostic characteristics in high-resolution computed tomography (HRCT) including ground-glass opacities, vascular enlargement, bilateral abnormalities, lower lobe involvement, and posterior preference, 45 patients with positive realtime polymerase chain reaction (PCR) test, eligible patients with respiratory symptoms (including dyspnea, chest pain or discomfort), oral temperature > 38°C and SpO 2 < 93% were included in the study.

Exclusion criteria were a history of myocardial ischemia, heart failure, and advanced COPD, mental retardation, direct admission to ICU, pregnancy, breastfeeding, a suspected or confirmed history of alcohol abuse or substance use disorder, and participation in other drug trials in the past month. After obtaining written informed consent, eligible patients were assigned to two groups of standard treatment (controls) and SQ plus standard treatment (cases) according to age, smoking habit, and past medical history, including DM, HTN, asthma, COPD, renal failure and liver failure. SQ treatment included intravenous injection of 5 mg SQ microemulsion twice a day for 6 days. The required dose for clinical study was selected based on the Fluad Influenza vaccine. Fluad Influenza vaccine contains 9.75 mg squalene in oily phase as an adjuvant. 46 In this study, 10 mg of SQ was chosen as the proposed dose for injection (5 mg SQ microemulsion twice a day). However, due to the severity of the COVID-19 pandemic, this dose was repeated for 6 days.

Vital signs and clinical characteristics, including respiratory rate, SpO 2 %, oral temperature, cough alleviation, and oral tolerance, were constantly assessed and recorded during the hospital admission. The assessors of symptoms were blinded.

Lung HRCT was repeated 7 days after the last dose of SQ. The severity of lung involvement was defined according to score (0 for no involvement, 1 for GGO, consolidation or nodule in a maximum of 2 lobes in an area less than one-third of each lobe, 2 for the involvement of 3 or 4 lobes with an area of less than one-third of each lobe or in 1 or 2 lobes with an area more than one-third of each lobe, 3 for the involvement of 5 lobes with an area of less than one-third of each lobe or in 3 lobes with an area more than one-third of each lobe and 4 for greater involvement). Variations in the lung involvement severity score were compared before and after treatment in the study groups.

All participants were monitored for adverse events including anaphylaxis, ALT or AST elevation more than 2.5-fold beyond the normal upper limit, total bilirubin elevation more than 1.5-fold beyond the normal upper limit, acute pancreatitis, and diarrhea.

It should be noted that squalene was previously administrated intravenously in the form of lipid emulsion. Toxicity or hypersensitive reaction was not reported. 38 In addition, in another study, vaccination with a subunit influenza vaccine with the MF59 adjuvant showed no antisqualene antibodies nor enhanced pre-existing antisqualene antibody titers. It confirmed that antisqualene antibodies are not increased by immunization with vaccines with the MF59 adjuvant. 23 These data extended the safety profile of the SQ emulsion.

Consequently, we applied SQ in the IV form for new application in COVID-19 treatment.

Data were analyzed using SPSS 18 software. The data analyst was blinded to the study groups. Qualitative variables were reported as number and percentage, and quantitative variables were expressed as median ± SD. Categorical variables were analyzed using the χ 2 test. Clinical outcomes and improved lung HRCT score 7 days after treatment were compared between groups using an independent t test. A value of p < 0.05 was considered to be significant. 

The purity of SQ was detected using FID-GC analysis. The result is shown in Figure 1 The zeta potential of the microemulsion sample was −32.01 mV, which is acceptable for a drug delivery system. The electrical conductivity coefficient of microemulsion was 467 μs/cm, which confirms the formation of an oil-in-water microemulsion. The refractive index of microemulsion was 1.391, which was near the aqueous phase. Therefore, it revealed the oil-in-water microemulsion with high transparency. The pH value was 6.52, which was close to pH value of the body environment and safe for oral usage. Following 3 and 6 months of preparation, no turbidity was observed in the sample, which confirms the high stability of the system. Furthermore, the sample was stable at 4℃, 25℃, and 40℃ without any sign of phase separation. Details of characterization at the preparation time and after 3 and 6 months are reported in Table 1 .

The rheogram of the SQ microemulsion is shown in Figure 3 Table 3 . As Table 3 shows, after 7 days of treatment, out of 15 patients in the control group, 1 (6.7%) needed no oxygen therapy, 9

(60%) received low flow, and 5 (33.3%) received high flow oxygen. In the experimental group, however, 8 (53.4%) patients did not need oxygen, 5 (33.3%) were on low flow and 2 (13.3%) were on high flow oxygen therapy. Hence, the need for oxygen therapy was significantly different between cases and controls after 7 days of treatment (p = 0.020). Conversion to severe or critical clinical status was 5 (33.3%) and 1 (16.7%), for control and case groups, respectively, which was statistically significant (p = 0.084). In 7 (46.7%) patients in the control group and 13 (86.7%) patients in the experimental group, no fever was registered at least for 2 days, which was significantly different between groups (p = 0.025). Cough alleviation was observed in 6 (40.0%) controls and 13 (86.7%) cases, and there was a significant difference between the two groups in this regard (p = 0.010).

Moreover, improvement in chest CT scan was reported in 4 (26.7%) controls and 10 (66.7%) cases, which varied significantly between the two groups (p = 0.033). Moreover, Sánchez-Quesada et al. claimed that SQ is capable of decreasing nuclear factor κB (NF-κB) expression. 48 NF-κB is a crucial transcription factor that produces many inflammatory genes and functions in both innate and adaptive immune cells. 51 Terpenoids are considered to be natural NF-κB pathway inhibitors with antiinflammatory and anticancer effects. 52 The NF-κB pathway appears to be a key element in COVID-19 natural progression and conversion to a severe phenotype. 53 The proteomic examination of SARS-CoV-2 infected lung tissue exhibited the upregulation of molecules associated with the NF-κB pathways reflecting the significant role of NF-κB in COVID pathogenesis. 54 Recent studies within vitro human lung models have shown that SARS-CoV-2 infection in the alveolar epithelium changes cell transcription toward an inflammatory program, and NF-κB-mediated inflammatory signaling is the most-upregulated pathway. 55 Accordingly, targeting the NF-κB pathway could reduce mortality in the severe form of COVID-19. [53] [54] [55] The antioxidant defense is a critical element in determining the severity of viral infections. 56 Respiratory viruses are associated with reactive oxygen species production and redox imbalance linked to inflammation and subsequent tissue damage. 57 Studies show that antioxidant deficiency may lead to viral mutation and exacerbate viral virulence in RNA viruses. 58 The SQ antioxidant properties have received increasing attention because its molecular features make it a potent quencher of singlet oxygen and free radicals. 26 Immune-modulating treatments in severe COVID-19 cases and antioxidant applications are considered as potential treatment strategies. 8, 64 The results of this clinical trial suggest that SQ microemulsion administration in severe cases of SARS-CoV-2 infected patients can improve several clinical outcomes.

In this clinical study, the efficacy of SQ microemulsion extracted from pumpkin seed oil was investigated to treatment COVID-19. Some Finally, understanding the mechanism of action of SQ microemulsion can extend our knowledge in designing new drugs for this pandemic treatment. This can be the subject of future work.

The conception and design of this study have been performed by Dr. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction

Features, Evaluation, and Treatment of Coronavirus

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard 2020

Is a "cytokine storm". Relevant to COVID-19?

Coronavirus infections: epidemiological, clinical and immunological features and hypotheses

Cytokine storm

Cytokine storm in COVID-19: the current evidence and treatment strategies

SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression

FDA approval of Remdesivir-a step in the right direction

COVID-19; current situation and recommended interventions

Terpenoids as therapeutic drugs and pharmaceutical agents

Synthetic metabolism and its significance in agriculture

more than a step toward sterols. Antioxidants

Methods for obtaining and determination of squalene from natural sources

Squalene protects against oxidative DNA damage in MCF10A human mammary epithelial cells but not in MCF7 and MDA-MB-231 human breast cancer cells

Significance of squalene in rice bran oil and perspectives on squalene oxidation

Current insights into the biological action of squalene

Squalene in a sex-dependent manner modulates atherosclerotic lesion which correlates with hepatic fat content in apoE-knockout male mice

Squalene: potential chemopreventive agent

Immunology and efficacy of MF59-adjuvanted vaccines

Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

Squalene targets pro-and anti-inflammatory mediators and pathways to modulate over-activation of neutrophils, monocytes and macrophages

Squalene as novel food factor

Biological importance and applications of squalene and squalane

Kinetic study of quenching reaction of singlet oxygen and scavenging reaction of free radical by squalene in n-butanol

chemistry, biological role, and therapeutic applications. Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids

Anti-virus research of triterpenoids in licorice

Novel antiviral agents: a medicinal plant perspective

Glycyrrhizin an active component of liquorice roots, and replication of SARS-associated coronavirus

Identification of natural compounds with antiviral activities against SARS-associated coronavirus

Small molecules targeting severe acute respiratory syndrome human coronavirus

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

Squalene is an antiviral compound for treating hepatitis C virus carriers. Google Patents

A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation

Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions

Fate of intravenously administered squalene and plant sterols in human subjects

The development of selfemulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance

A novel experimental method for adsorption of fatty acids from pumpkin seed oil in the presence of iron oxide nanoparticles: Experimental and SA-LOOCV-GRBF mathematical modeling

A novel method for squalene extraction from pumpkin seed oil using magnetic nanoparticles and exploring the inhibition effect of extracted squalene on angiogenesis property

Preparation, characterization and in vitro evaluation of microemulsion of raloxifene hydrochloride

Preparation, characterization and in-vivo evaluation of microemulsions containing tamoxifen citrate anticancer drug

The development of selfemulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance, pharmaceutics, drug delivery and pharmaceutical technology

Imaging signature of coronavirus disease 2019 infection: in pursuit of the scientific evidence

US Package Insert

Formulation, clinical and histopathological assessment of microemulsion based hydrogel for UV protection of skin

Squalene stimulates a key innate immune cell to foster wound healing and tissue repair

Matrix metalloproteinases as modulators of inflammation and innate immunity

Fernandez-Patron C. Identification of fibrinogen as a natural inhibitor of MMP-2

NF-κB signaling in inflammation

Terpenoids: natural inhibitors of NF-kappaB signaling with antiinflammatory and anticancer potential

The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients

Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples

SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response

Mild SARS-CoV-2 infections in children might be based on evolutionary biology and linked with host reactive oxidative stress and antioxidant capabilities

Redox biology of respiratory viral infections

Host nutritional status: the neglected virulence factor

Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats

Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatininduced cytotoxicity in vivo without protecting tumor growth

Pharmacokinetics and biodistribution of squalene-containing emulsion adjuvant following intramuscular injection of H5N1 influenza vaccine in mice

Squalene emulsions for parenteral vaccine and drug delivery

Squalane-based emulsion vaccine delivery system: composition with murabutide activate Th1 response

COVID-19: immunology and treatment options

Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID-19: A clinical study

The authors declare that there are no conflict of interests.

http://orcid.org/0000-0002-9419-7435